908 Devices Inc. (MASS) Earnings

Management highlights

### Core Revenue & Profitability Progress - Q2 2026 delivered $16.1 million total revenue (23% YoY growth), with U.S. state and local customers accounting for over half of total revenue, supported by sustained public funding for detection capability modernization to address fentanyl, synthetic drugs, and chemical hazards. - Adjusted EBITDA loss improved 50% YoY to less than $2 million, driven by 2025 cost structure optimization initiatives, demonstrating efficient scaling alongside growth investment. ### Strategic Focus Area 1: Scaling Proven Platforms - Over 750 FTIR devices shipped in the past 24 months, confirming a large, addressable modernization opportunity; 35+ VIPER FTIR devices shipped in Q2, putting the firm on track to hit the 2026 full-year target of 100+ VIPER shipments. - Notable Q2 wins include a 15-unit competitive displacement order from a major South Asian law enforcement agency, a first VIPER order from the Bureau of International Narcotics and Law Enforcement Affairs for Mexican narcotic interdiction, and a 15-unit MX-908 order for Texas statewide correctional facilities. - 908 Devices products were included in the security toolkit for 2026 FIFA World Cup stadiums, providing high-visibility field validation for first responder customers. A $6 million protector order for an Asia-Pacific corrections agency was secured in July 2026, carrying momentum into Q3. ### Strategic Focus Area 2: Extending Platform Leadership - Explorer (Xplor) gas and vapor detection device placements grew nearly 70% in the 12 months ending June 30 2026, driven by rising domestic chemical incidents (up 20% YoY to 131 serious accidents in 2025) and increased international defense demand. - The Danish Defense Acquisition and Logistics Organization selected Explorer for an initial multi-unit procurement with a future purchase framework agreement, validating the platform's differentiated performance for defense applications. ### Strategic Focus Area 3: Strengthening Revenue Durability - The May 2026 acquisition of NearLab added an AI-powered, cloud-connected, subscription-based near-infrared narcotics detection platform, completing a comprehensive end-to-end workflow for law enforcement from initial screening to confirmatory analysis. - Regulatory tailwinds support NearLab adoption: Colorado has banned custodial arrests based solely on error-prone colorimetric test kits, with reform efforts underway in at least 7 other U.S. states, creating durable demand for connected, auditable digital detection. - In the two months post-acquisition, 35+ NearLab devices with multi-year software subscriptions have been sold to customers in the U.S., Morocco, and Iceland, meeting initial post-close expectations, with a growing pipeline of enterprise-scale opportunities.

Guidance

- 908 Devices updated its 2026 full-year revenue guidance to $68 million to $70 million, representing 21% to 25% YoY growth over 2025, raising the lower bound of the prior guidance range driven by year-to-date performance and the July $6 million protector order. - Handheld product and service revenue is now expected to grow 23% to 27% YoY to a range of $65 million to $67 million, while OEM and funded partnership revenue is projected to remain approximately $3 million, unchanged from prior guidance. - The U.S. military AVCAD program is excluded from core 2026 guidance, with any future revenue from AVCAD counted as upside to the stated range as the program works through next steps. - Full-year 2026 adjusted gross margins are projected to remain in the mid-to-high 50% range, consistent with prior guidance. - Adjusted EBITDA loss is expected to shrink to the mid-single-digit millions for full-year 2026, maintaining the prior outlook as the firm progresses toward breakeven while continuing growth investment.

Segment performance

908 Devices reports total Q2 2026 revenue of $16.1 million, a 23% year-over-year (YoY) increase. Handheld product and service revenue, the firm's primary operating segment, reached $15.5 million (96.3% of total revenue), growing 24% YoY, driven by FTIR product shipments including 35+ VIPER units and initial NearLab revenue. Recurring revenue, the secondary segment, totaled $4.9 million (31% of total revenue), a 4% YoY increase, supported by software, accessories, and FTIR service revenue, partially offset by an expected reduction in legacy mass spec service revenue. Gross profit for Q2 2026 was $8.3 million with a 52% gross margin, up from $6.4 million and 49% YoY. Adjusted gross profit was $9.2 million with a 57% adjusted gross margin, an 85 basis point increase YoY.

Risks & headwinds

- The AVCAD program procurement process is delayed as the U.S. Department of Defense evaluates both the existing custom development path and a potential shift to commercial off-the-shelf products, creating uncertainty around near-term revenue timing for the program. - NearLab is in early commercial integration post-acquisition, has not yet reached scale, and contributes lower gross margins on hardware than 908 Devices' core mature products, which may temper near-term margin expansion. - Recurring revenue as a percentage of total revenue fluctuates quarter-to-quarter based on the volume of new one-time hardware placements, creating near-term variability in the firm's revenue mix profile.

Analyst Q&A

• Q: With the expanded product portfolio post-NearLab acquisition, what bundling opportunities exist with government and law enforcement customers, and are multi-system orders common? /

  A: 908 Devices already sees multi-system bundled orders across its core FTIR and MX product lines, with growing bundling potential for NearLab. NearLab complements the existing product portfolio, enabling a complete end-to-end narcotics workflow: NearLab handles initial screening, while MX and VIPER handle confirmatory analysis. Bundling is also common across hazmat and fire service customers, pairing Explorer with FTIR Threat ID devices. NearLab is still new, but its complementary capabilities make it well-suited for future cross-selling and bundling.

• Q: If AVCAD shifts to a direct commercial off-the-shelf award to 908 Devices, how would that impact revenue ramp and potential? /

  A: Management retains full confidence in winning the AVCAD opportunity regardless of the path, either as a partner to Smith Detection or directly with the commercial MX-908. Higher product content for 908, which would come with a direct award, improves the program's economics for the firm. AVCAD is still expected to be a $10 million+ long-term opportunity, but timing of the ramp remains to be determined, so it is excluded from 2026 guidance and counted as upside.

• Q: What is the medium-term target for recurring revenue as a percentage of total revenue, as newer subscription-based products like NearLab scale? /

  A: The current baseline for recurring revenue is ~30% of total revenue, with quarterly fluctuations ranging from high-20s to low-30s based on the volume of new hardware placements in a given period. Over time, the NearLab subscription model (which generates 50% recurring revenue per unit) will create a snowball effect from the growing installed base. Management aspires to grow recurring revenue to approach 40% of total revenue over the medium term as the subscription model scales.

• Q: What is the current cloud attach rate for 908 Devices products, and what is the long-term target for cloud-connected recurring subscriptions? /

  A: The existing Team Leader cloud platform already has hundreds of users supporting core FTR products today. The NearLab acquisition established a proven 50% recurring subscription model: a ~$10,000 upfront device cost paired with ~$5,000 annual subscription, with high customer retention (over 90% renewal rates) and multi-year upfront subscriptions common. Management aims to replicate this model broadly across the 908 Devices product portfolio over time, with 50% recurring as a long-term target for the full business.

• Q: How much of Q2 2026's product gross margin expansion is structural vs. temporary volume/mix, and how do Viper and NearLab impact full-year margin expectations? /

  A: Q2 2026 adjusted gross margin came in at 57%, up from 56.7% for full-year 2025, driven by structural improvements including a lower post-restructuring cost base and favorable channel mix (higher share of lower-channel-cost U.S. state and local sales). For full-year 2026, adjusted gross margin is expected to hold near 56% in the mid-to-high 50% range: lower-margin NearLab (not yet at scale), the discounted high-volume $6 million international protector order, and early-stage Viper production will temper further margin expansion, offsetting structural gains from higher volume and lower costs.